LEADER 02821nam 2200565 a 450 001 9910463934103321 005 20200520144314.0 010 $a1-283-14446-8 010 $a9786613144461 010 $a981-4304-44-1 035 $a(CKB)3360000000001369 035 $a(EBL)731248 035 $a(OCoLC)740446114 035 $a(SSID)ssj0000522004 035 $a(PQKBManifestationID)12250886 035 $a(PQKBTitleCode)TC0000522004 035 $a(PQKBWorkID)10522612 035 $a(PQKB)10293844 035 $a(MiAaPQ)EBC731248 035 $a(WSP)00001226 035 $a(Au-PeEL)EBL731248 035 $a(CaPaEBR)ebr10480040 035 $a(CaONFJC)MIL314446 035 $a(EXLCZ)993360000000001369 100 $a20101007d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDiabetic retinopathy$b[electronic resource] /$f[edited by] Jose? Cunha-Vaz 210 $aHackensack, N.J. $cWorld Scientific$d2010 215 $a1 online resource (450 p.) 300 $aTwo columns to the page. 311 $a981-4304-43-3 320 $aIncludes bibliographical references and index. 327 $aStandards of medical care in diabetes, 2009 / American Diabetes Association -- Clinical presentation of retinopathy / Jose? Cunha-Vaz -- Clinical diagnostic methodologies -- Pathogenesis -- Epidemiology / Jose? Rui Faria Abreu -- Major clinical trials on treatment for diabetic retinopathy / Luisa Ribeiro -- Photocoagulation for macular edema and proliferative retinopathy / Francisco Gome?z-Ulla -- Vitrectomy for diabetic retinopathy / Jose? Carlos Pastor -- Medical management of diabetic retinopathy / Jose? Rui Faria Abreu and Jose? Cunha-Vaz -- An integrated perspective on diabetic retinopathy in type 2 diabetes / Jose? Cunha-Vaz. 330 $aThis book addresses diabetic retinopathy, an eye disease that remains one of the main causes of vision loss if not diagnosed and managed properly. It aims to cover the entire spectrum of the disease by describing its clinical identification and characterization, pathophysiology, epidemiology, and medical and surgical management. ""Diabetic Retinopathy"" also offers a complete overview of the present understanding of diabetic retinopathy, covering current practice but also including original contributions that offer novel perspectives for looking at and addressing this disease. The author has d 606 $aDiabetic retinopathy 608 $aElectronic books. 615 0$aDiabetic retinopathy. 676 $a617.7/35 701 $aCunha-Vaz$b Jose? G$0784991 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910463934103321 996 $aDiabetic retinopathy$92155207 997 $aUNINA LEADER 02928nam 2200469 450 001 9910583337903321 005 20230120002745.0 010 $a0-12-809302-1 010 $a0-12-805353-4 035 $a(CKB)4100000001577946 035 $a(MiAaPQ)EBC5217571 035 $a(EXLCZ)994100000001577946 100 $a20180212h20182018 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aNeuromodulation $ecomprehensive textbook of principles, technologies, and therapies /$fedited by Elliot S. Krames, P. Hunter Peckham, Ali R. Rezai 205 $aSecond edition. 210 1$aLondon, England :$cAcademic Press,$d2018. 210 4$dİ2018 215 $a1 online resource (1,844 pages) $ccolor illustrations, tables 320 $aIncludes bibliographical references at the end of each chapters. 327 $aVolume 1. Section I: Defining neuromodulation -- Section II: The brain initiative: implications for a revolutionary change in clinical medicine via neuromodulation technology -- Section III: Fundamentals and mechanisms of neuromodulation -- Section IV: Technology and devices -- Section V: Brain, computer and machine interfacing -- Section VI: Emerging technologies and techniques -- Section VII: Surgical procedures and techniques -- Volume 2. Section VIII: Neuromodulation for pain control -- Section VIII A: Spinal cord stimulation for pain control -- Section VIII B: Peripheral nerve stimulation for pain control introduction: peripheral nerve stimulation for pain control -- Section VIII C: Intrathecal therapies for pain control and the control of spasticity -- Section VIII D: Intracranial procedures for chronic pain -- Section X: Neurostimulation for epilepsy -- Section XI: Neuromodulation for behavioral and cognitive disorders -- Volume 3. Section XII: Neuromodulation for functional restoration -- Section XIII: Neuromodulation for organ systems -- Section XIII A: Neuromodulation for cardiovascular disorders -- Section XIII B: Neuromodulation for pulmonary disorders -- Section XIII C: Neuromodulation for gastrointestinal disorders -- Section XIII D: Neuromodulation for urogenital disorders -- Section XIV: Neuromodulation for endocrine, immune, and inflammatory disorders -- Section XV: Noninvasive neuromodulation -- Section XVI: The business end of neuromodulation. 606 $aNeural transmission$xRegulation 606 $aNeurotransmitters 606 $aNeural stimulation 615 0$aNeural transmission$xRegulation. 615 12$aNeurotransmitters. 615 0$aNeural stimulation. 676 $a573.854 702 $aRezai$b Ali R. 702 $aPeckham$b P. Hunter 702 $aPeckham$b Elliot S. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910583337903321 996 $aNeuromodulation$91916100 997 $aUNINA